Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

0.7685 +0.0185 (+2.47%)
Streaming Delayed Price Updated: 12:28 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Citius Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Citius Pharma Plans Interim Analysis for Mino-Lok By End of June ↗
Citius Pharmaceuticals Inc (NASDAQ: CTXR) announced that the subsequent planned interim analysis for its Phase 3 trial of Mino-Lok for catheter-related bloodstream... 
Via Benzinga
News headline image
EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages ↗
Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga's Global Small Cap Conference for an... 
Via Benzinga
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Aldeyra Therapeutics (NASDAQ:ALDX) stock moved upwards by 25.29% to $13.92 during Tuesday's pre-market session. The company's market cap stands at $661.8... 
Via Benzinga
News headline image
Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19 ↗
The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Assertio Holdings (NASDAQ:ASRT) stock increased by 19.41% to $0.62 during Thursday's pre-market session. The company's market cap stands at $107.3 million... 
Via Benzinga
News headline image
Exclusive: Citius Pharmaceuticals Exec Chairman On Product Pipeline, Potential $1B TAM ↗
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own money in the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.